Nu Skin Enterprises (NUS) 10-Q 8 May 24 2024 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 01, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Document Transition Report	false
Entity File Number	001-12421
Entity Registrant Name	NU SKIN ENTERPRISES, INC.
Entity Central Index Key	0001021561
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0565309
Entity Address, Address Line One	75 West Center Street
Entity Address, City or Town	Provo
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84601
City Area Code	801
Local Phone Number	345-1000
Title of 12(b) Security	Class A Common Stock, $.001 par value
Trading Symbol	NUS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,667,403

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 212,532	$ 256,057
Current investments	8,674	11,759
Accounts receivable, net	67,041	72,879
Inventories, net	265,100	279,978
Prepaid expenses and other	93,913	81,198
Total current assets	647,260	701,871
Property and equipment, net	422,818	432,965
Operating lease right-of-use assets	93,092	90,107
Goodwill	230,768	230,768
Other intangible assets, net	101,933	105,309
Other assets	246,044	245,443
Total assets	1,741,915	1,806,463
Current liabilities:
Accounts payable	32,237	43,505
Accrued expenses	247,068	260,366
Current portion of long-term debt	30,000	25,000
Total current liabilities	309,305	328,871
Operating lease liabilities	74,198	70,943
Long-term debt	453,183	478,040
Other liabilities	95,023	106,641
Total liabilities	931,709	984,495
Commitments and contingencies (Notes 5 and 11)
Stockholders' equity:
Class A common stock - 500 million shares authorized, $0.001 par value, 90.6 million shares issued	91	91
Additional paid-in capital	618,706	621,853
Treasury stock, at cost - 40.9 million and 41.1 million shares	(1,564,942)	(1,570,440)
Accumulated other comprehensive loss	(110,607)	(100,006)
Retained earnings	1,866,958	1,870,470
Total stockholders' equity	810,206	821,968
Total liabilities and stockholders' equity	$ 1,741,915	$ 1,806,463

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares shares in Millions	Mar. 31, 2024	Dec. 31, 2023
Stockholders' equity:
Common stock, shares authorized (in shares)	500	500
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares issued (in shares)	90.6	90.6
Treasury stock (in shares)	40.9	41.1

Consolidated Statements of Inco

Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Consolidated Statements of Income [Abstract]
Revenue	$ 417,306	$ 481,462
Cost of sales	123,242	133,588
Gross profit	294,064	347,874
Operating expenses:
Selling expenses	153,542	188,124
General and administrative expenses	124,566	133,899
Restructuring and impairment expenses	7,134	9,787
Total operating expenses	285,242	331,810
Operating income	8,822	16,064
Interest expense	7,325	4,888
Other income (expense), net	(396)	3,412
Income before provision for income taxes	1,101	14,588
Provision for income taxes	1,634	3,212
Net (loss) income	$ (533)	$ 11,376
Net (loss) income per share (Note 6):
Basic (in dollars per share)	$ (0.01)	$ 0.23
Diluted (in dollars per share)	$ (0.01)	$ 0.23
Weighted-average common shares outstanding:
Basic (in shares)	49,538	49,644
Diluted (in shares)	49,538	50,058

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Consolidated Statements of Comprehensive Income [Abstract]
Net (loss) income	$ (533)	$ 11,376
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustment, net of taxes of $- and $(68) for the three months ended March 31, 2024 and 2023, respectively	(10,104)	(2,139)
Net unrealized gains/(losses) on cash flow hedges, net of taxes of $(435) and $175 for the three months ended March 31, 2024 and 2023, respectively	1,574	(635)
Reclassification adjustment for realized losses/(gains) in current earnings, net of taxes of $572 and $475 for the three months ended March 31, 2024 and 2023, respectively	(2,071)	(1,722)
Other comprehensive loss, net of tax	(10,601)	(4,496)
Comprehensive (loss) income	$ (11,134)	$ 6,880

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustment, tax	$ 0	$ (68)
Net unrealized gains/(losses) on foreign currency cash flow hedges, tax	(435)	175
Reclassification adjustment for realized losses/(gains) in current earnings on cash flow hedges, tax	$ 572	$ 475

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member] Class A [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Retained Earnings [Member]	Total
Balance at beginning of period at Dec. 31, 2022	$ 91	$ 613,278	$ (1,569,061)	$ (86,509)	$ 1,939,497	$ 897,296
Stockholders' Equity [Roll Forward]
Net (loss) income	0	0	0	0	11,376	11,376
Other comprehensive loss, net of tax	0	0	0	(4,496)	0	(4,496)
Exercise of employee stock options/vesting of stock awards	0	(5,797)	9,981	0	0	4,184
Stock-based compensation	0	4,002	0	0	0	4,002
Cash dividends	0	0	0	0	(19,392)	(19,392)
Balance at end of period at Mar. 31, 2023	91	611,483	(1,559,080)	(91,005)	1,931,481	892,970
Balance at beginning of period at Dec. 31, 2023	91	621,853	(1,570,440)	(100,006)	1,870,470	821,968
Stockholders' Equity [Roll Forward]
Net (loss) income	0	0	0	0	(533)	(533)
Other comprehensive loss, net of tax	0	0	0	(10,601)	0	(10,601)
Exercise of employee stock options/vesting of stock awards	0	(7,389)	5,498	0	0	(1,891)
Stock-based compensation	0	4,242	0	0	0	4,242
Cash dividends	0	0	0	0	(2,979)	(2,979)
Balance at end of period at Mar. 31, 2024	$ 91	$ 618,706	$ (1,564,942)	$ (110,607)	$ 1,866,958	$ 810,206

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - shares shares in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stockholders' Equity [Roll Forward]
Exercise of employee stock options (in shares)	0.2	0.4

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net (loss) income	$ (533)	$ 11,376
Adjustments to reconcile net (loss) income to cash flows from operating activities:
Depreciation and amortization	18,437	16,983
Non-cash lease expense	7,987	8,566
Stock-based compensation	4,242	4,002
Inventory write-down	2,003	3,267
Foreign currency losses / (gains)	1,639	(2,102)
Loss / (gain) on disposal of assets	218	(17)
Deferred taxes	1,348	(72)
Changes in operating assets and liabilities:
Accounts receivable, net	7,447	(15,336)
Inventories, net	6,999	(23,001)
Prepaid expenses and other	(13,352)	(12,895)
Other assets	(4,295)	(864)
Accounts payable	(10,575)	(4,495)
Accrued expenses	(4,227)	(4,129)
Other liabilities	(14,020)	(3,360)
Net cash provided by / (used in) operating activities	3,318	(22,077)
Cash flows from investing activities:
Purchases of property and equipment	(12,281)	(11,487)
Proceeds on investment sales	3,019	4,986
Purchases of investments	0	(8,195)
Net cash used in investing activities	(9,262)	(14,696)
Cash flows from financing activities:
Exercise of employee stock options and taxes paid related to the net shares settlement of stock awards	(1,891)	4,184
Payment of cash dividends	(2,979)	(19,392)
Finance lease principal payments	(785)	(912)
Contingent consideration payments	(6,300)	0
Payments of debt	(20,000)	(2,500)
Proceeds from debt	0	20,000
Net cash (used in) / provided by financing activities	(31,955)	1,380
Effect of exchange rate changes on cash	(5,626)	609
Net decrease in cash and cash equivalents	(43,525)	(34,784)
Cash and cash equivalents, beginning of period	256,057	264,725
Cash and cash equivalents, end of period	$ 212,532	$ 229,941

The Company

The Company	3 Months Ended
	Mar. 31, 2024
The Company [Abstract]
The Company	1. The Company Nu Skin Enterprises, Inc. (the “Company”) is a holding company, with Nu Skin being the primary operating unit. Nu Skin develops and distributes premium-quality, innovative beauty and wellness products that are sold worldwide under the Nu Skin, Pharmanex and ageLOC brands and a small number of other products and services. The Company reports revenue from nine segments, consisting of its seven geographic Nu Skin segments —Americas, , , Australia, New Zealand, and other markets; South Korea;

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) The unaudited consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information as of March and for the -month periods ended March and The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. The consolidated balance sheet as of December has been prepared using information from the audited financial statements at that date. For further information, refer to the consolidated financial statements and accompanying footnotes included in the Company’s Annual Report on Form -K for the year ended December Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (CODM), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss. Public entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with a single reportable segment are required to provide all the disclosures required by the amendments in the update and existing segment disclosures in Topic 280. This amendment is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company will adopt this standard with its fiscal 2024 annual filing. The Company is currently evaluating these new disclosure requirements and the impact of adoption. Reclassifications Certain prior period amounts have been reclassified to conform with current presentation. The Company reclassified $4.9 million of interest expense from other income (expense), net to the interest expense Inventory Inventories consist of the following (U.S. dollars in thousands): March 31, 2024 December 31, 2023 Raw materials $ 133,600 $ 140,133 Finished goods 131,500 139,845 Total Inventory, net $ 265,100 $ 279,978 Reserves of inventories consist of the following (U.S. dollars in thousands): Three Months Ended March 31, 2024 2023 Beginning balance $ 83,378 $ 37,267 Additions 2,003 3,267 Write-offs (4,862 ) (4,518 ) Ending Balance $ 80,519 $ 36,016 Revenue Recognition Contract Liabilities – Customer Loyalty Programs Contract liabilities, recorded as deferred revenue within the accrued expenses line in the consolidated balance sheets, include loyalty point program deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as points are redeemed for additional products. The balance of deferred revenue related to contract liabilities as of March and December was and , respectively. The contract liabilities impact to revenue for the -month periods ended March and was an increase of vely.

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2024
Goodwill [Abstract]
Goodwill	3. Goodwill The Company’s reporting units for goodwill are its operating segments, which are also its reportable segments, with the exception of Rhyz other. The Company’s Rhyz other segment consists of three During the three months ended March 31, 2024, the Company determined that the recent decline in the Company’s stock price and corresponding market capitalization was a triggering event that required the Company to perform a quantitative impairment analysis for all reporting units. Based on the analysis, the Company concluded the fair value of all reporting units were in excess of their carrying amounts and no impairment charge was required. For goodwill, the estimated fair value of all reporting units exceeded the carrying value by approximately 1% - 7%; therefore the reporting units are considered to be at risk of future impairment. The reporting units’ fair values remain sensitive to unfavorable changes in assumptions utilized including revenue growth rates, profitability margins, estimated future cash flows, and the discount rates that could result in impairment charges in a future period. The following table presents goodwill allocated to the Company’s reportable segments for the periods ended and December 31, 2023 (U.S. dollars in thousands): March 31, 2024 December 31, 2023 Nu Skin Americas $ 9,449 $ 9,449 Mainland China 32,179 32,179 Southeast Asia/Pacific 18,537 18,537 Japan 16,019 16,019 Europe & Africa 2,875 2,875 South Korea 29,261 29,261 Hong Kong/Taiwan 6,634 6,634 Rhyz Investments Manufacturing 78,875 78,875 Rhyz other 36,939 36,939 Total $ 230,768 $ 230,768

Debt

Debt	3 Months Ended
	Mar. 31, 2024
Debt [Abstract]
Debt	4. Debt Credit Agreement On June 14, 2022, the Company entered into an Amended and Restated Credit Agreement (the “Credit Agreement”) with several financial institutions as lenders and Bank of America, N.A., as administrative agent, which amended and restated the 2018 Credit Agreement. The Credit Agreement provides for a $400 million term loan facility and a $500 million revolving credit facility, each with a term of five years. Both facilities bear interest at the SOFR, plus a margin based on the Company’s consolidated leverage ratio. Commitment fees payable under the Credit Agreement are also based on the consolidated leverage ratio as defined in the Credit Agreement and range from 0.175% to 0.30% on the unused portion of the total lender commitments then in effect. The term loan facility amortizes in quarterly installments in amounts resulting in an annual amortization of 2.5% during the first year and 5.0% during the second, third, fourth and fifth years after the closing date of the Credit Agreement, with the remainder payable at final maturity. The Credit Agreement is guaranteed by certain of the Company’s domestic subsidiaries and collateralized by assets of such subsidiaries, including a pledge of 65% of the capital stock of certain foreign subsidiaries. The Credit Agreement requires the Company to maintain a consolidated leverage ratio not exceeding 2.75 to 1.00 and a consolidated interest coverage ratio of no less than 3.00 to 1.00. As of March 31, 2024, the Company was in compliance with all covenants under the Credit Agreement. The following table summarizes the Company’s debt facilities as of March 31, 2024 and December 31, 2023: Facility or Arrangement Original Principal Amount Balance as of March 31, 2024 (1)(2) Balance as of December 31, 2023 (1)(2) Interest Rate Repayment Terms Credit Agreement term loan facility $400.0 million $375.0 million $385.0 million Variable 21% of the principal amount is payable Credit Agreement revolving credit facility $110.0 million $120.0 million Variable Revolving line of credit expires June 14, 2027. (1) As of March 31, 2024 and December 31, 2023, the current portion of the Company’s debt (i.e., becoming due in the next 12 months) included $20.0 million and $25.0 million, respectively, of the balance of its term loan under the Credit Agreement and $10.0 million and zero, respectively, of the balance under the revolving line of credit. (2) The carrying value of the debt reflects the amounts stated in the above table, less debt issuance costs of $1.8 million and $ million as of and December 31, 2023, respectively, related to the Credit Agreement, which are not reflected in this table.

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leases	5. Leases As of . The components of lease expense were as follows (U.S. dollars in thousands): Three Months Ended March 31 2024 2023 Operating lease expense Operating lease cost $ 6,066 $ 8,161 Variable lease cost 1,776 1,075 Finance lease expense Amortization of right-of-use assets 758 1,000 Interest on lease liabilities 109 134 Total lease expense $ 8,709 $ 10,370 Supplemental cash flow information related to leases was as follows (U.S. dollars in thousands): Three March 31 2024 2023 Operating cash outflow from operating leases $ 6,371 $ 8,150 Operating cash outflow from finance leases $ 111 $ 132 Financing cash outflow from finance leases $ 785 $ 912 Right-of-use assets obtained in exchange for operating lease obligations $ 13,034 $ 7,981 Right-of-use assets obtained in exchange for finance lease obligations $ 5 $ 520 Maturities of lease liabilities were as follows (U.S. dollars in thousands): Year Ending December 31 Operating Leases Finance Leases 2024 $ 18,576 $ 2,541 2025 19,920 3,305 2026 15,170 3,213 2027 11,496 2,882 2028 8,531 47 Thereafter 36,730 — Total 110,423 11,988 Less: Finance charges 15,306 795 Total principal liability $ 95,117 $ 11,193

Capital Stock

Capital Stock	3 Months Ended
	Mar. 31, 2024
Capital Stock [Abstract]
Capital Stock	6. Capital Stock Net income per share Net income per share is computed based on the weighted-average number of common shares outstanding during the periods presented. Additionally, diluted earnings per share data gives effect to all potentially dilutive common shares that were outstanding during the periods presented. For the three-month periods ended March 31, 2024 and 2023, the only dilutive common shares outstanding relate to the Company’s outstanding stock awards and options. For the three-month periods ended March 31, 2024 and 2023, stock awards and options of 1.8 million and 0.1 million, respectively, were excluded from the calculation of diluted earnings per share because they were anti-dilutive. Dividends In February 2024 May 2024 Repurchase of common stock During the three-month periods ended March 31, 2024 and 2023, the Company repurchased zero shares of its Class A common stock under its stock repurchase plans. As of March 31, 2024, $162.4 million was available for repurchases under the Company’s stock repurchase plan.

Fair Value and Equity Investmen

Fair Value and Equity Investments	3 Months Ended
	Mar. 31, 2024
Fair Value and Equity Investments [Abstract]
Fair Value and Equity Investments	7. Fair Value and Equity Investments Fair Value The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximates fair values due to the short-term nature of these instruments. The carrying value of debt approximates fair value due to the variable 30-day interest rate. Fair value estimates are made at a specific point in time, based on relevant market information. The FASB Codification defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. On a quarterly basis, the Company measures at fair value certain financial assets, including cash equivalents. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair-value hierarchy: ■ Level 1 – quoted prices in active markets for identical assets or liabilities; ■ Level 2 – inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and ■ Level 3 – unobservable inputs based on the Company’s own assumptions. Accounting standards permit companies, at their option, to measure certain financial instruments and other eligible items at fair value. The Company has elected not to apply the fair value option to existing eligible items beyond what is required by US GAAP. The following tables present the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis (U.S. dollars in thousands): Fair Value at March 31, 2024 Level 1 Level 2 Level 3 Total Financial assets (liabilities): Cash equivalents and current investments $ 34,571 $ — $ — $ 34,571 Derivative financial instruments asset — 12,054 — 12,054 Life insurance contracts — — 48,414 48,414 Contingent consideration — — — — Total $ 34,571 $ 12,054 $ 48,414 $ 95,039 Fair Value at December 31, 2023 Level 1 Level 2 Level 3 Total Financial assets (liabilities): Cash equivalents and current investments $ 42,916 $ — $ — $ 42,916 Derivative financial instruments asset — 12,689 — 12,689 Life insurance contracts — — 45,041 45,041 Contingent consideration — — (6,300 ) (6,300 ) Total $ 42,916 $ 12,689 $ 38,741 $ 94,346 The following table provides a summary of changes in fair value of the Company’s Level 3 life insurance contracts (U.S. dollars in thousands): 2024 2023 Beginning balance at January 1 $ 45,041 $ 40,055 Actual return on plan assets 3,373 1,998 Ending balance at March 31 $ 48,414 $ 42,053 Life insurance contracts: The following table provides a summary of changes in fair value of the Company’s Level 3 contingent consideration (U.S. dollars in thousands): 2024 2023 Beginning balance at January 1 $ (6,300 ) $ (6,364 ) Changes in fair value of contingent consideration — 93 Payments 6,300 — Ending balance at March 31 $ — $ (6,271 ) Contingent consideration: Equity Investments The Company maintains equity investments in companies which are accounted for under the measurement alternative described in ASC - - - for equity securities that lack readily determinable fair values. The carrying amount of equity securities held by the Company without readily determinable fair values was at each of March 31, 2024 and December During the months ended September the Company recognized upward fair value adjustments, based on the valuation of additional equity issued by the investee which was deemed to be an observable transaction of a similar investment under ASC was recorded within Other income (expense), net on the Consolidated Statement of Income. The upward fair value adjustment represents a nonrecurring fair value measurement based on observable price changes and is classified as a Level fair value measurement.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Taxes [Abstract]
Income Taxes	8. Income Taxes Provision for income taxes for the first quarter of 2024 was $1.6 million, compared to $3.2 million for the prior-year period. The effective tax rate for the first quarter 2024 was 148.4% of pre-tax income compared to 22.0% in the prior-year period. The Company accounts for income taxes in accordance with ASC Topic 740 “Income Taxes.” These standards establish financial accounting and reporting standards for the effects of income taxes that result from an enterprise’s activities during the current and preceding years. The Company takes an asset and liability approach for financial accounting and reporting of income taxes. The Company pays income taxes in many foreign jurisdictions based on the profits realized in those jurisdictions, which can be significantly impacted by terms of intercompany transactions between the Company and its foreign affiliates. Deferred tax assets and liabilities are created in this process. The Company has netted these deferred tax assets and deferred tax liabilities by jurisdiction. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized. The Company had net deferred tax assets of $105.6 million and $105.0 million as of March 31, 2024 and December 31, 2023, respectively. The Company evaluates its indefinite reinvestment assertions with respect to foreign earnings for each quarter. For all foreign earnings, the Company accrues the applicable foreign income taxes. For the earnings that have been indefinitely reinvested, the Company does not accrue foreign withholding taxes. Undistributed earnings that the Company has indefinitely reinvested, for which no foreign withholding taxes have been provided, aggregate to $60.0 million as of December 31, 2023. If the amount designated as indefinitely reinvested as of December 31, 2023 was repatriated to the United States, the amount of incremental taxes would be approximately $6.0 million. The Company intends to utilize the indefinitely reinvested offshore earnings to fund foreign investments, specifically capital expenditures. The Company files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. In 2009, the Company entered into a voluntary program with the IRS called Compliance Assurance Process (“CAP”). The objective of CAP is to contemporaneously work with the IRS to achieve federal tax compliance and resolve all or most of the issues prior to filing of the tax return. As of December 31, 2023, tax years through 2020 and 2022 have been audited and are effectively closed to further examination. For tax year 2021, the Company was in the Bridge phase of the CAP program, pursuant to which the IRS will not accept disclosures, will not conduct reviews and will not provide letters of assurance for the Bridge years. There are limited circumstances that tax years in the Bridge phase will be opened for examination. For tax years 2023 and 2024, the Company has been accepted in the IRS’s Bridge Plus program. The Company may elect to continue participating in CAP for future tax years; the Company may withdraw from the program at any time. With a few exceptions, the Company is no longer subject to state and local income tax examination by tax authorities for the years before 2020. Foreign jurisdictions have varying lengths of statutes of limitations for income tax examinations. Some statutes are as short as three years and in certain markets may be as long as ten years. The Company is currently under examination in certain foreign jurisdictions; however, the outcomes of those reviews are not yet determinable. The Company’s unrecognized tax benefits relate to multiple jurisdictions. Due to potential increases in unrecognized tax benefits from the multiple jurisdictions in which the Company operates, as well as the expiration of various statutes of limitations, it is reasonably possible that the Company’s gross unrecognized tax benefits, net of foreign currency adjustments, may increase in the next 12 months by approximately $2.0 to $3.0 million. In 2021, as part of the Organization for Economic Co-operation and Development’s (“OECD”) Inclusive Framework, 140 member countries agreed to the implementation of the Pillar Two Global Minimum Tax (“Pillar Two”) of 15%. The OECD continues to release additional guidance, including administrative guidance on how Pillar Two rules should be interpreted and applied by jurisdictions as they adopt Pillar Two. A number of countries have utilized the administrative guidance as a starting point for legislation that went into effect January 1, 2024. Based on current enacted legislation, the Company anticipates the impact of Pillar Two to be immaterial for 2024.

Derivatives and Hedging Activit

Derivatives and Hedging Activities	3 Months Ended
	Mar. 31, 2024
Derivatives and Hedging Activities [Abstract]
Derivatives and Hedging Activities	9. Derivatives and Hedging Activities Risk Management Objective of Using Derivatives The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings. Cash Flow Hedges of Interest Rate Risk The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. During 2024, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt. For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income and subsequently reclassified into interest expense/income in the same period(s) during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense/income as interest payments are made/received on the Company’s variable-rate debt. During the next twelve months, the Company estimates that an additional $9.5 million will be reclassified as a reduction to interest expense. As of March 31, 2024 and December 31, 2023, the Company had four outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk with a total notional amount of $200 million. Fair Values of Derivative Instruments on the Balance Sheet The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Balance Sheet: Fair Values of Derivative Instruments Derivatives in Cash flow Hedging Relationships: Balance Sheet Location March 31, 2024 December 31, 2023 Interest Rate Swap - Asset Prepaid expenses and other $ 9,451 $ 8,955 Interest Rate Swap - Asset Other assets $ 2,603 $ 3,734 Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss The tables below present the effect of cash flow hedge accounting on Accumulated Other Comprehensive Loss. Amount of Gain (Loss) Recognized in OCI on Derivatives Three Months Ended Derivatives in Cash flow March 31, Hedging Relationships: 2024 2023 Interest Rate Swaps $ 2,009 $ (810 ) Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Income Three Months Ended Derivatives in Cash flow Income Statement March 31, Hedging Relationships: Location 2024 2023 Interest Rate Swaps Other income (expense), net $ 2,643 $ 2,197

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2024
Segment Information [Abstract]
Segment Information	10. Segment Information The Company reports revenue from nine segments, consisting of its seven geographic Nu Skin segments— Americas, Mainland China, Southeast Asia/Pacific, South Korea, Japan, Europe & Africa, and Hong Kong/Taiwan Company’s Profitability by segment as determined under US GAAP is driven primarily by the Company’s transfer pricing policies. Segment contribution, which is the Company’s segment profitability metric presented in the table below, excludes certain intercompany charges, specifically royalties, license fees, transfer pricing, discrete charges and other miscellaneous items. These charges have been included in Corporate and other expenses. Corporate and other expenses also include costs related to the Company’s executive and administrative offices, information technology, research and development, and marketing and supply chain functions not recorded at the segment level. Effective June 2023, the Company closed its Israel market. As a result the EMEA segment has been renamed Europe & Africa. The accounting policies of the segments are the same as those described in Note 2 – Summary of Significant Accounting Policies. The Company evaluates the performance of its segments based on revenue and segment contribution. Each segment records direct expenses related to its employees and its operations. Summarized financial information for the Company’s reportable segments is shown in the following tables. Asset information is not reviewed or included with the Company’s internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment. Revenue by Segment Three Months Ended March 31, (U.S. dollars in thousands) 2024 2023 Nu Skin Americas $ 75,031 $ 101,157 Mainland China 61,067 67,976 Southeast Asia/Pacific 60,065 67,810 Japan 44,236 52,606 Europe & Africa 42,273 47,444 South Korea 40,963 70,324 Hong Kong/Taiwan 30,466 34,548 Other 672 (115 ) Total Nu Skin 354,773 441,750 Rhyz Investments Manufacturing (1) 50,302 35,767 Rhyz other 12,231 3,945 Total Rhyz Investments 62,533 39,712 Total $ 417,306 $ 481,462 (1) The Rhyz Investments Manufacturing segment had $ 8.6 11.8 Segment Contribution Three Months Ended March 31, (U.S. dollars in thousands) 2024 2023 Nu Skin Americas $ 14,976 $ 16,250 Mainland China 12,253 13,612 Southeast Asia/Pacific 11,084 12,471 Japan 12,006 12,908 Europe & Africa 3,276 3,638 South Korea 12,183 23,575 Hong Kong/Taiwan 7,367 7,834 Nu Skin contribution 73,145 90,288 Rhyz Investments Manufacturing 1,967 (1,373 ) Rhyz other (5,942 ) (1,960 ) Total (3,975 ) (3,333 ) Total segment contribution 69,170 86,955 Corporate and other (60,348 ) (70,891 ) Operating income 8,822 16,064 Interest expense 7,325 4,888 Other income (expense), net (396 ) 3,412 Income before provision for income taxes $ 1,101 $ 14,588 Depreciation and Amortization Three Months Ended March 31, (U.S. dollars in thousands) 2024 2023 Nu Skin Americas $ 105 $ 66 Mainland China 2,774 2,775 Southeast Asia/Pacific 249 280 Japan 81 1,054 Europe & Africa 273 282 South Korea 245 453 Hong Kong/Taiwan 579 453 Total Nu Skin 4,306 5,363 Rhyz Investments Manufacturing 3,335 3,424 Rhyz other 1,886 592 Total Rhyz Investments 5,221 4,016 Corporate and other 8,910 7,604 Total $ 18,437 $ 16,983 Capital Expenditures Three Months Ended March 31, (U.S. dollars in thousands) 2024 2023 Nu Skin Americas $ 21 $ 100 Mainland China 2,689 4,035 Southeast Asia/Pacific 9 64 Japan — 5 Europe & Africa 165 119 South Korea 22 154 Hong Kong/Taiwan 198 260 Total Nu Skin 3,104 4,737 Rhyz Investments Manufacturing 1,349 1,481 Rhyz other 635 — Total Rhyz Investments 1,984 1,481 Corporate and other 7,193 5,269 Total $ 12,281 $ 11,487

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies The Company is subject to government regulations pertaining to product formulation, labeling and packaging, product claims and advertising, and the Company’s direct selling system. The Company is also subject to the jurisdiction of numerous foreign tax and customs authorities. Any assertions or determination that either the Company or the Company’s sales force is not in compliance with existing statutes, laws, rules or regulations could have a material adverse effect on the Company’s operations. In addition, in any country or jurisdiction, the adoption of new statutes, laws, rules or regulations or changes in the interpretation of existing statutes, laws, rules or regulations could have a material adverse effect on the Company and its operations. No assurance can be given that the Company’s compliance with applicable statutes, laws, rules and regulations will not be challenged by foreign authorities or that such challenges will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company and its Subsidiaries are defendants in litigation, investigations and other proceedings involving various matters. Management believes that the ultimate liability arising from such claims and contingencies, if any, is not likely to have a material adverse effect on the Company’s consolidated financial condition, results of operations or cash flows. The Company is subject to regular audits by federal, state and foreign tax authorities. These audits may result in additional tax liabilities. The Company believes it has appropriately provided for income taxes for all years. Several factors drive the calculation of its tax reserves. Some of these factors include: (i) the expiration of various statutes of limitations; (ii) changes in tax law and regulations; (iii) issuance of tax rulings; and (iv) settlements with tax authorities. Changes in any of these factors may result in adjustments to the Company’s reserves, which would impact its reported financial results.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2024
Acquisitions [Abstract]
Acquisitions	12. Acquisitions In April 2023, the Company acquired 60 percent of LifeDNA, Inc. (“LifeDNA”), a DNA assessment company. Consideration paid included $4.0 million of cash, along with the conversion of a previous $3.0 million Simple Agreement for Future Equity (“SAFE”), and a $0.2 million convertible note. The acquisition enables the Company to continue to expand its digital tools. The Company allocated the fair value of $12.0 million to the assets acquired and liabilities assumed at estimated fair values. The estimated fair value of assets acquired included $7.3 million of intangible assets, $1.7 million of cash, $0.1 million of current assets, $0.9 million of accrued liabilities and also resulted in a deferred tax liability of $0.9 million. The excess purchase price over the aggregate fair value of assets acquired less liabilities assumed of $4.7 million was recorded as goodwill. The goodwill recognized is attributable primarily to expected synergies. None of the goodwill is expected to be deductible for income tax purposes. The intangible assets acquired comprised $0.6 million of customer relationships, $1.7 million of technology, $1.0 million of tradenames and $4.1 million of other intangibles. The intangibles were assigned useful lives of 7 years for the technology, tradenames and other intangibles, and 2 years for the customer relationships. All the goodwill was assigned to our Rhyz other segment. The numbers above are stated net of measurement period adjustments recorded during the fourth quarter of 2023 of $1.1 million to deferred tax liability and goodwill. The allocation of the fair value of assets acquired and liabilities assumed for the acquisition was finalized during the three months ended December 31, 2023. In June 2023, the Company acquired 100 percent ownership in Beauty Biosciences, LLC (“BeautyBio”), making BeautyBio a wholly owned subsidiary of the Company. The acquisition expands the Company’s product and device offerings within its Rhyz segment. The purchase price for BeautyBio was $75.0 million, net of cash acquired of $1.5 million, all payable in cash. The Company allocated the gross purchase price of $76.5 million to the assets acquired and liabilities assumed at estimated fair values. The estimated fair value of assets acquired included $43.0 million of intangible assets, $1.5 million of cash, $3.5 million of accounts receivable, $10.3 million of inventory, $0.8 million of prepaid and other assets, $1.0 million of fixed assets, $1.2 million of an ROU operating lease asset and corresponding lease liability, $2.5 million of accounts payable and accrued liabilities and also resulted in a deferred tax liability of $0.7 million. The excess purchase price over the aggregate fair value of assets acquired less liabilities assumed of $19.6 million was recorded as goodwill. The goodwill recognized is attributable primarily to expected synergies. None of the goodwill is expected to be deductible for income tax purposes. The intangible assets acquired comprised $18.4 million of customer relationships, $2.3 million of technology, $20.9 million of tradenames and $1.4 million of other intangibles. The intangibles were assigned useful lives of approximately 19 years for the technology and tradenames, approximately 9 years for the customer relationships and 3 years for the other intangibles. All the goodwill was assigned to our Rhyz other segment. The numbers above are stated net of measurement period adjustments recorded during the fourth quarter of 2023 of $(1.2) million to accounts receivable, $(0.7) million of inventory, $(0.5) million of accrued liabilities, $0.7 million of deferred tax liability, $(0.3) of intangible assets and $2.4 million of goodwill. The allocation of the fair value of assets acquired and liabilities assumed for the acquisition was finalized during the three months ended March 31, 2024. The financial results of LifeDNA and BeautyBio are included in the Rhyz other segment from the date of acquisition. For the three months ended March 31, 2024, the Company included $5.3 million of revenue from these acquisitions. The unaudited pro forma revenue for the Company, including LifeDNA and BeautyBio, as if the acquisitions occurred on January 1, 2023, would have been $486.3 million for the three months ended March 31, 2023.

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2024
Restructuring [Abstract]
Restructuring	13. Restructuring In the third quarter of 2022, the Company adopted a strategic plan (“2022 Plan”) to focus resources on the Company’s strategic priorities and optimize future growth and profitability. The global program includes workforce reductions and footprint optimization. The Company incurred total charges under the program of approximately $53.3 million, with $40.8 million in cash charges of severance and lease termination cost and approximately $12.5 million of non-cash charges of impairment of fixed assets, acceleration of depreciation and impairment of other intangibles related to the footprint optimization. During 2022, the Company incurred charges to be settled in cash of $20.1 million in severance charges, $7.4 million in lease termination cost, and $5.2 million in other associated cost, and non-cash charges of $8.2 million in fixed asset impairments, $0.9 million in accelerated depreciation and $1.7 million in impairment of other intangibles. During 2022, the Company made cash payments of $21.0 million related to this global program, leaving an ending restructuring accrual of $11.7 million. During the first quarter and full year of 2023, the Company incurred charges to be settled in cash of $4.0 million in severance charges, $1.9 million in lease termination cost, and $2.2 million in other associated cost, and non-cash charges of $1.7 million in accelerated depreciation. In 2023, the Company made cash payments of $19.8 million, leaving no restructuring accrual related to this plan as of December 31, 2023. Restructuring expense by segment - 2022 Plan (U.S. dollars in thousands) Three Months Ended March 31, 2023 Year Ended December 31, 2022 Total Nu Skin Americas $ 918 $ 1,687 $ 2,605 Mainland China 1,352 13,181 14,533 Southeast Asia/Pacific 131 1,809 1,940 Japan 1,515 699 2,214 Europe & Africa (113 ) 2,143 2,030 South Korea 422 1,533 1,955 Hong Kong/Taiwan (201 ) 2,464 2,263 Total Nu Skin 4,024 23,516 27,540 Rhyz Investments Manufacturing 13 401 414 Rhyz other — — — Total Rhyz Investments 13 401 414 Corporate and other 5,750 19,577 25,327 Total $ 9,787 $ 43,494 $ 53,281 In the fourth quarter of 2023, the Company adopted another strategic plan (“2023 Plan”) to focus resources on the Company’s global priorities and optimize future growth and profitability. The global program includes workforce reductions. The Company estimates total charges under the program will approximate $20–$25 million in cash charges of severance. The Company expects to substantially complete the program during the first half of 2024. During the fourth quarter of 2023, the Company incurred charges to be settled in cash of $10.0 million in severance charges. During the fourth quarter of 2023, the Company made cash payments of $0.3 million, leaving an ending restructuring accrual of $9.7 million. During the first quarter of 2024, the Company incurred charges to be settled in cash of $4.1 million in severance charges and $2.0 million in other associated cost, and non-cash charges of $1.0 million in write-down of assets. During the first quarter of 2024, the Company made cash payments of $7.0 million, leaving an ending restructuring accrual of $8.8 million. R Three Months Ended (U.S. dollars in thousands) March 31, 2024 December 31, 2023 Total Nu Skin Americas $ 3,145 $ 598 $ 3,743 Mainland China 1,017 2,910 3,927 Southeast Asia/Pacific 307 862 1,169 Japan 24 — 24 Europe & Africa 677 554 1,231 South Korea 134 — 134 Hong Kong/Taiwan 357 432 789 Total Nu Skin 5,661 5,356 11,017 Rhyz Investments Manufacturing — — — Rhyz other — — — Total Rhyz Investments — — — Corporate and other 1,473 4,647 6,120 Total $ 7,134 $ 10,003 $ 17,137

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Accounting	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”)
Consolidation	The unaudited consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.
Accounting Pronouncements	Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (CODM), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss. Public entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with a single reportable segment are required to provide all the disclosures required by the amendments in the update and existing segment disclosures in Topic 280. This amendment is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company will adopt this standard with its fiscal 2024 annual filing. The Company is currently evaluating these new disclosure requirements and the impact of adoption.
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform with current presentation. The Company reclassified $4.9 million of interest expense from other income (expense), net to the interest expense
Revenue Recognition	Revenue Recognition Contract Liabilities – Customer Loyalty Programs Contract liabilities, recorded as deferred revenue within the accrued expenses line in the consolidated balance sheets, include loyalty point program deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as points are redeemed for additional products. The balance of deferred revenue related to contract liabilities as of March and December was and , respectively. The contract liabilities impact to revenue for the -month periods ended March and was an increase of vely.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Inventories	Inventories consist of the following (U.S. dollars in thousands): March 31, 2024 December 31, 2023 Raw materials $ 133,600 $ 140,133 Finished goods 131,500 139,845 Total Inventory, net $ 265,100 $ 279,978
Inventory Reserves	Reserves of inventories consist of the following (U.S. dollars in thousands): Three Months Ended March 31, 2024 2023 Beginning balance $ 83,378 $ 37,267 Additions 2,003 3,267 Write-offs (4,862 ) (4,518 ) Ending Balance $ 80,519 $ 36,016

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2024
Goodwill [Abstract]
Goodwill	The following table presents goodwill allocated to the Company’s reportable segments for the periods ended and December 31, 2023 (U.S. dollars in thousands): March 31, 2024 December 31, 2023 Nu Skin Americas $ 9,449 $ 9,449 Mainland China 32,179 32,179 Southeast Asia/Pacific 18,537 18,537 Japan 16,019 16,019 Europe & Africa 2,875 2,875 South Korea 29,261 29,261 Hong Kong/Taiwan 6,634 6,634 Rhyz Investments Manufacturing 78,875 78,875 Rhyz other 36,939 36,939 Total $ 230,768 $ 230,768

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2024
Debt [Abstract]
Debt Facilities	The following table summarizes the Company’s debt facilities as of March 31, 2024 and December 31, 2023: Facility or Arrangement Original Principal Amount Balance as of March 31, 2024 (1)(2) Balance as of December 31, 2023 (1)(2) Interest Rate Repayment Terms Credit Agreement term loan facility $400.0 million $375.0 million $385.0 million Variable 21% of the principal amount is payable Credit Agreement revolving credit facility $110.0 million $120.0 million Variable Revolving line of credit expires June 14, 2027. (1) As of March 31, 2024 and December 31, 2023, the current portion of the Company’s debt (i.e., becoming due in the next 12 months) included $20.0 million and $25.0 million, respectively, of the balance of its term loan under the Credit Agreement and $10.0 million and zero, respectively, of the balance under the revolving line of credit. (2) The carrying value of the debt reflects the amounts stated in the above table, less debt issuance costs of $1.8 million and $ million as of and December 31, 2023, respectively, related to the Credit Agreement, which are not reflected in this table.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Components of Lease Expense	The components of lease expense were as follows (U.S. dollars in thousands): Three Months Ended March 31 2024 2023 Operating lease expense Operating lease cost $ 6,066 $ 8,161 Variable lease cost 1,776 1,075 Finance lease expense Amortization of right-of-use assets 758 1,000 Interest on lease liabilities 109 134 Total lease expense $ 8,709 $ 10,370
Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows (U.S. dollars in thousands): Three March 31 2024 2023 Operating cash outflow from operating leases $ 6,371 $ 8,150 Operating cash outflow from finance leases $ 111 $ 132 Financing cash outflow from finance leases $ 785 $ 912 Right-of-use assets obtained in exchange for operating lease obligations $ 13,034 $ 7,981 Right-of-use assets obtained in exchange for finance lease obligations $ 5 $ 520
Maturities of Lease Liabilities	Maturities of lease liabilities were as follows (U.S. dollars in thousands): Year Ending December 31 Operating Leases Finance Leases 2024 $ 18,576 $ 2,541 2025 19,920 3,305 2026 15,170 3,213 2027 11,496 2,882 2028 8,531 47 Thereafter 36,730 — Total 110,423 11,988 Less: Finance charges 15,306 795 Total principal liability $ 95,117 $ 11,193

Fair Value and Equity Investm_2

Fair Value and Equity Investments (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value and Equity Investments [Abstract]
Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables present the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis (U.S. dollars in thousands): Fair Value at March 31, 2024 Level 1 Level 2 Level 3 Total Financial assets (liabilities): Cash equivalents and current investments $ 34,571 $ — $ — $ 34,571 Derivative financial instruments asset — 12,054 — 12,054 Life insurance contracts — — 48,414 48,414 Contingent consideration — — — — Total $ 34,571 $ 12,054 $ 48,414 $ 95,039 Fair Value at December 31, 2023 Level 1 Level 2 Level 3 Total Financial assets (liabilities): Cash equivalents and current investments $ 42,916 $ — $ — $ 42,916 Derivative financial instruments asset — 12,689 — 12,689 Life insurance contracts — — 45,041 45,041 Contingent consideration — — (6,300 ) (6,300 ) Total $ 42,916 $ 12,689 $ 38,741 $ 94,346
Changes in Fair Value of Level 3 Life Insurance Contracts	The following table provides a summary of changes in fair value of the Company’s Level 3 life insurance contracts (U.S. dollars in thousands): 2024 2023 Beginning balance at January 1 $ 45,041 $ 40,055 Actual return on plan assets 3,373 1,998 Ending balance at March 31 $ 48,414 $ 42,053
Changes in Fair Value of Level 3 Contingent Consideration	The following table provides a summary of changes in fair value of the Company’s Level 3 contingent consideration (U.S. dollars in thousands): 2024 2023 Beginning balance at January 1 $ (6,300 ) $ (6,364 ) Changes in fair value of contingent consideration — 93 Payments 6,300 — Ending balance at March 31 $ — $ (6,271 )

Derivatives and Hedging Activ_2

Derivatives and Hedging Activities (Tables)	3 Months Ended
	Mar. 31, 2024
Derivatives and Hedging Activities [Abstract]
Fair Value of Derivative Instruments on the Balance Sheet	The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Balance Sheet: Fair Values of Derivative Instruments Derivatives in Cash flow Hedging Relationships: Balance Sheet Location March 31, 2024 December 31, 2023 Interest Rate Swap - Asset Prepaid expenses and other $ 9,451 $ 8,955 Interest Rate Swap - Asset Other assets $ 2,603 $ 3,734
Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss	The tables below present the effect of cash flow hedge accounting on Accumulated Other Comprehensive Loss. Amount of Gain (Loss) Recognized in OCI on Derivatives Three Months Ended Derivatives in Cash flow March 31, Hedging Relationships: 2024 2023 Interest Rate Swaps $ 2,009 $ (810 ) Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Income Three Months Ended Derivatives in Cash flow Income Statement March 31, Hedging Relationships: Location 2024 2023 Interest Rate Swaps Other income (expense), net $ 2,643 $ 2,197

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2024
Segment Information [Abstract]
Revenue by Segment	Revenue by Segment Three Months Ended March 31, (U.S. dollars in thousands) 2024 2023 Nu Skin Americas $ 75,031 $ 101,157 Mainland China 61,067 67,976 Southeast Asia/Pacific 60,065 67,810 Japan 44,236 52,606 Europe & Africa 42,273 47,444 South Korea 40,963 70,324 Hong Kong/Taiwan 30,466 34,548 Other 672 (115 ) Total Nu Skin 354,773 441,750 Rhyz Investments Manufacturing (1) 50,302 35,767 Rhyz other 12,231 3,945 Total Rhyz Investments 62,533 39,712 Total $ 417,306 $ 481,462 (1) The Rhyz Investments Manufacturing segment had $ 8.6 11.8
Segment Contribution	Segment Contribution Three Months Ended March 31, (U.S. dollars in thousands) 2024 2023 Nu Skin Americas $ 14,976 $ 16,250 Mainland China 12,253 13,612 Southeast Asia/Pacific 11,084 12,471 Japan 12,006 12,908 Europe & Africa 3,276 3,638 South Korea 12,183 23,575 Hong Kong/Taiwan 7,367 7,834 Nu Skin contribution 73,145 90,288 Rhyz Investments Manufacturing 1,967 (1,373 ) Rhyz other (5,942 ) (1,960 ) Total (3,975 ) (3,333 ) Total segment contribution 69,170 86,955 Corporate and other (60,348 ) (70,891 ) Operating income 8,822 16,064 Interest expense 7,325 4,888 Other income (expense), net (396 ) 3,412 Income before provision for income taxes $ 1,101 $ 14,588
Depreciation and Amortization and Capital Expenditures	Depreciation and Amortization Three Months Ended March 31, (U.S. dollars in thousands) 2024 2023 Nu Skin Americas $ 105 $ 66 Mainland China 2,774 2,775 Southeast Asia/Pacific 249 280 Japan 81 1,054 Europe & Africa 273 282 South Korea 245 453 Hong Kong/Taiwan 579 453 Total Nu Skin 4,306 5,363 Rhyz Investments Manufacturing 3,335 3,424 Rhyz other 1,886 592 Total Rhyz Investments 5,221 4,016 Corporate and other 8,910 7,604 Total $ 18,437 $ 16,983 Capital Expenditures Three Months Ended March 31, (U.S. dollars in thousands) 2024 2023 Nu Skin Americas $ 21 $ 100 Mainland China 2,689 4,035 Southeast Asia/Pacific 9 64 Japan — 5 Europe & Africa 165 119 South Korea 22 154 Hong Kong/Taiwan 198 260 Total Nu Skin 3,104 4,737 Rhyz Investments Manufacturing 1,349 1,481 Rhyz other 635 — Total Rhyz Investments 1,984 1,481 Corporate and other 7,193 5,269 Total $ 12,281 $ 11,487

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2024
2022 Plan [Member]
Restructuring [Abstract]
Restructuring Expense by Segment	Restructuring expense by segment - 2022 Plan (U.S. dollars in thousands) Three Months Ended March 31, 2023 Year Ended December 31, 2022 Total Nu Skin Americas $ 918 $ 1,687 $ 2,605 Mainland China 1,352 13,181 14,533 Southeast Asia/Pacific 131 1,809 1,940 Japan 1,515 699 2,214 Europe & Africa (113 ) 2,143 2,030 South Korea 422 1,533 1,955 Hong Kong/Taiwan (201 ) 2,464 2,263 Total Nu Skin 4,024 23,516 27,540 Rhyz Investments Manufacturing 13 401 414 Rhyz other — — — Total Rhyz Investments 13 401 414 Corporate and other 5,750 19,577 25,327 Total $ 9,787 $ 43,494 $ 53,281
2023 Plan [Member]
Restructuring [Abstract]
Restructuring Expense by Segment	R Three Months Ended (U.S. dollars in thousands) March 31, 2024 December 31, 2023 Total Nu Skin Americas $ 3,145 $ 598 $ 3,743 Mainland China 1,017 2,910 3,927 Southeast Asia/Pacific 307 862 1,169 Japan 24 — 24 Europe & Africa 677 554 1,231 South Korea 134 — 134 Hong Kong/Taiwan 357 432 789 Total Nu Skin 5,661 5,356 11,017 Rhyz Investments Manufacturing — — — Rhyz other — — — Total Rhyz Investments — — — Corporate and other 1,473 4,647 6,120 Total $ 7,134 $ 10,003 $ 17,137

The Company (Details)

The Company (Details)	3 Months Ended
	Mar. 31, 2024 Segment
The Company [Abstract]
Number of reportable segments	9
Number of geographic segments	7
Number of Rhyz segments	2

Summary of Significant Accoun_4

Summary of Significant Accounting Policies, Reclassifications (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Interest Expense [Abstract]
Interest expense	$ 7,325	$ 4,888
Reclassification [Member] | Other Income (Expense), Net [Member]
Interest Expense [Abstract]
Interest expense		(4,900)
Reclassification [Member] | Interest Expense [Member]
Interest Expense [Abstract]
Interest expense		$ 4,900

Summary of Significant Accoun_5

Summary of Significant Accounting Policies, Inventory (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Inventories [Abstract]
Raw materials	$ 133,600		$ 140,133
Finished goods	131,500		139,845
Total Inventory, net	265,100		$ 279,978
Valuation Allowance [Roll Forward]
Beginning balance	83,378	$ 37,267
Additions	2,003	3,267
Write-offs	(4,862)	(4,518)
Ending balance	$ 80,519	$ 36,016

Summary of Significant Accoun_6

Summary of Significant Accounting Policies, Revenue Recognition (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Contract Liabilities - Customer Loyalty Programs [Abstract]
Contract liabilities for customer loyalty programs	$ 11.9		$ 12.6
Contract liabilities, increase to revenue	$ 0.7	$ 1.3

Goodwill (Details)

Goodwill (Details)	3 Months Ended	6 Months Ended
	Mar. 31, 2024 USD ($) ReportingUnit	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Goodwill [Abstract]
Impairment of goodwill		$ 0
Goodwill	$ 230,768,000	230,768,000	$ 230,768,000
Americas [Member]
Goodwill [Abstract]
Goodwill	9,449,000	9,449,000	9,449,000
Mainland China [Member]
Goodwill [Abstract]
Goodwill	32,179,000	32,179,000	32,179,000
Southeast Asia/Pacific [Member]
Goodwill [Abstract]
Goodwill	18,537,000	18,537,000	18,537,000
Japan [Member]
Goodwill [Abstract]
Goodwill	16,019,000	16,019,000	16,019,000
Europe & Africa [Member]
Goodwill [Abstract]
Goodwill	2,875,000	2,875,000	2,875,000
South Korea [Member]
Goodwill [Abstract]
Goodwill	29,261,000	29,261,000	29,261,000
Hong Kong/Taiwan [Member]
Goodwill [Abstract]
Goodwill	6,634,000	6,634,000	6,634,000
Manufacturing [Member]
Goodwill [Abstract]
Goodwill	$ 78,875,000	78,875,000	78,875,000
Rhyz Other [Member]
Goodwill [Abstract]
Number of reporting units | ReportingUnit	3
Goodwill	$ 36,939,000	36,939,000	36,939,000
Rhyz Other [Member] | Reporting Unit 1 [Member]
Goodwill [Abstract]
Goodwill	12,600	12,600	12,600
Rhyz Other [Member] | Reporting Unit 2 [Member]
Goodwill [Abstract]
Goodwill	19,600	19,600	19,600
Rhyz Other [Member] | Reporting Unit 3 [Member]
Goodwill [Abstract]
Goodwill	$ 4,700	$ 4,700	$ 4,700
Minimum [Member]
Goodwill [Abstract]
Percentage of fair value in excess of carrying amount	1%	1%
Maximum [Member]
Goodwill [Abstract]
Percentage of fair value in excess of carrying amount	7%	7%

Debt, Credit Agreement (Details

Debt, Credit Agreement (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Jun. 14, 2022
Credit Agreement [Member]
Debt [Abstract]
Percentage of capital stock of certain foreign subsidiaries pledged as collateral	65%
Credit Agreement [Member] | Minimum [Member]
Debt [Abstract]
Commitment fee percentage payable on unused portion	0.175%
Consolidated interest coverage ratio	3
Credit Agreement [Member] | Maximum [Member]
Debt [Abstract]
Commitment fee percentage payable on unused portion	0.30%
Consolidated leverage ratio	2.75
Term Loan Facility [Member]
Debt [Abstract]
Original principal amount	$ 400	$ 400
Term of loan	5 years
Term Loan Facility [Member] | First Year [Member]
Debt [Abstract]
Annual amortization percentage	2.50%
Term Loan Facility [Member] | Second Year [Member]
Debt [Abstract]
Annual amortization percentage	5%
Term Loan Facility [Member] | Third Year [Member]
Debt [Abstract]
Annual amortization percentage	5%
Term Loan Facility [Member] | Fourth Year [Member]
Debt [Abstract]
Annual amortization percentage	5%
Term Loan Facility [Member] | Fifth Year [Member]
Debt [Abstract]
Annual amortization percentage	5%
Revolving Credit Facility [Member]
Debt [Abstract]
Borrowing capacity		$ 500
Term of loan	5 years

Debt, Debt Facilities (Details)

Debt, Debt Facilities (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2024	Dec. 31, 2023	Jun. 14, 2022
Debt [Abstract]
Term of variable rate		30 days
Current portion of long-term debt		$ 30,000	$ 25,000
Credit Agreement [Member]
Debt [Abstract]
Unamortized debt issuance costs		1,800	2,000
Credit Agreement Term Loan Facility [Member]
Debt [Abstract]
Original principal amount		400,000		$ 400,000
Balance	[1],[2]	$ 375,000	385,000
Interest rate		Variable 30 day: 7.43%
Interest rate		7.43%
Term of variable rate		30 days
Repayment terms		21% of the principal amount is payable in increasing quarterly installments over a five-year period that began on September 30, 2022, with the remainder payable at the end of the five-year term.
Percentage of principal payable in installments		21%
Term of loan		5 years
Current portion of long-term debt		$ 20,000	25,000
Credit Agreement Revolving Credit Facility [Member]
Debt [Abstract]
Balance	[1],[2]	$ 110,000	120,000
Interest rate		Variable 30 day: 7.43%
Interest rate		7.43%
Term of variable rate		30 days
Repayment terms		Revolving line of credit expires June 14, 2027.
Term of loan		5 years
Current portion of long-term debt		$ 10,000	$ 0
[1]As of March 31, 2024 and December 31, 2023, the current portion of the Company’s debt (i.e., becoming due in the next 12 months) included $20.0 million and $25.0 million, respectively, of the balance of its term loan under the Credit Agreement and $10.0 million and zero, respectively, of the balance under the revolving line of credit.[2]The carrying value of the debt reflects the amounts stated in the above table, less debt issuance costs of $1.8 million and $ million as of and December 31, 2023, respectively, related to the Credit Agreement, which are not reflected in this table.

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Weighted-average remaining lease term for operating leases	8 years 2 months 12 days
Weighted-average remaining lease term for finance leases	3 years 6 months
Weighted-average discount rate for operating leases	3.80%
Weighted-average discount rate for finance leases	3.70%
Operating Lease Expense [Abstract]
Operating lease cost	$ 6,066	$ 8,161
Variable lease cost	1,776	1,075
Finance Lease Expense [Abstract]
Amortization of right-of-use assets	758	1,000
Interest on lease liabilities	109	134
Total lease expense	8,709	10,370
Supplemental Cash Flow Information Related to Leases [Abstract]
Operating cash outflow from operating leases	6,371	8,150
Operating cash outflow from finance leases	111	132
Financing cash outflow from finance leases	785	912
Right-of-use assets obtained in exchange for operating lease obligations	13,034	7,981
Right-of-use assets obtained in exchange for finance lease obligations	5	$ 520
Maturities of Operating Lease Liabilities [Abstract]
2024	18,576
2025	19,920
2026	15,170
2027	11,496
2028	8,531
Thereafter	36,730
Total	110,423
Less: Finance charges	15,306
Total principal liability	95,117
Maturities of Financing Lease Liabilities [Abstract]
2024	2,541
2025	3,305
2026	3,213
2027	2,882
2028	47
Thereafter	0
Total	11,988
Less: Finance charges	795
Total principal liability	$ 11,193

Capital Stock, Net Income per S

Capital Stock, Net Income per Share (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock Awards and Options [Member]
Net Income per Share [Abstract]
Anti-dilutive shares excluded from calculation of diluted earnings per share (in shares)	1.8	0.1

Capital Stock, Dividends (Detai

Capital Stock, Dividends (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	May 31, 2024	Feb. 28, 2023	Mar. 31, 2024	Mar. 31, 2023
Dividends per Share [Abstract]
Payment of cash dividends			$ 2,979	$ 19,392
Dividend Declared 2024-Q1 [Member]
Dividends per Share [Abstract]
Dividend payable, date declared			2024-02
Dividend payable per share (in dollars per share)		$ 0.06
Payment of cash dividends		$ 3,000
Dividend payable, date paid			Mar. 06, 2024
Dividend payable, date of record			Feb. 26, 2024
Dividend Declared 2024-Q2 [Member] | Subsequent Event [Member]
Dividends per Share [Abstract]
Dividend payable, date declared	2024-05
Dividend payable per share (in dollars per share)	$ 0.06
Dividend payable, date paid	Jun. 12, 2024
Dividend payable, date of record	May 31, 2024

Capital Stock, Repurchase of Co

Capital Stock, Repurchase of Common Stock (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Repurchases of Common Stock [Abstract]
Amount available for repurchases	$ 162.4
Treasury Stock [Member]
Repurchases of Common Stock [Abstract]
Class A common stock repurchased (in shares)	0	0

Fair Value and Equity Investm_3

Fair Value and Equity Investments, Fair Value (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Fair Value and Equity Investments [Abstract]
Term of variable rate	30 days
Contingent Consideration [Member]
Changes in Fair Value of Level 3 Contingent Consideration [Roll Forward]
Beginning balance	$ (6,300)	$ (6,364)
Changes in fair value of contingent consideration	0	93
Payments	6,300	0
Ending balance	0	(6,271)
Fair Value on a Recurring Basis [Member]
Financial Assets (Liabilities) [Abstract]
Cash equivalents and current investments	34,571		$ 42,916
Derivative financial instruments asset	12,054		12,689
Life insurance contracts	48,414		45,041
Contingent consideration	0		(6,300)
Financial assets (liabilities)	95,039		94,346
Fair Value on a Recurring Basis [Member] | Level 1 [Member]
Financial Assets (Liabilities) [Abstract]
Cash equivalents and current investments	34,571		42,916
Derivative financial instruments asset	0		0
Life insurance contracts	0		0
Contingent consideration	0		0
Financial assets (liabilities)	34,571		42,916
Fair Value on a Recurring Basis [Member] | Level 2 [Member]
Financial Assets (Liabilities) [Abstract]
Cash equivalents and current investments	0		0
Derivative financial instruments asset	12,054		12,689
Life insurance contracts	0		0
Contingent consideration	0		0
Financial assets (liabilities)	12,054		12,689
Fair Value on a Recurring Basis [Member] | Level 3 [Member]
Financial Assets (Liabilities) [Abstract]
Cash equivalents and current investments	0		0
Derivative financial instruments asset	0		0
Life insurance contracts	48,414		45,041
Contingent consideration	0		(6,300)
Financial assets (liabilities)	48,414		$ 38,741
Life Insurance Contracts [Member]
Changes in Fair Value of Level 3 Marketable Securities [Roll Forward]
Beginning balance	45,041	40,055
Actual return on plan assets	3,373	1,998
Ending balance	$ 48,414	$ 42,053

Fair Value and Equity Investm_4

Fair Value and Equity Investments, Equity Investments (Details) - Equity Securities [Member] - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2021	Mar. 31, 2024	Dec. 31, 2023
Equity Investments [Abstract]
Carrying amount of equity securities without readily determinable fair values		$ 28.1	$ 28.1
Other Income (Expense), Net [Member]
Equity Investments [Abstract]
Upward fair value adjustments on equity securities	$ 18.1

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Income Taxes [Abstract]
Provision for income taxes	$ 1,634	$ 3,212
Effective tax rate	148.40%	22%
Net deferred tax assets	$ 105,600		$ 105,000
Undistributed earnings of non-U.S. subsidiaries			60,000
Incremental taxes if undistributed earnings on non-U.S. subsidiaries were repatriated			$ 6,000
Minimum [Member]
Income Taxes [Abstract]
Increase in unrecognized tax benefits within the next 12 months that is reasonably possible	2,000
Maximum [Member]
Income Taxes [Abstract]
Increase in unrecognized tax benefits within the next 12 months that is reasonably possible	$ 3,000
Foreign Jurisdictions [Member] | Minimum [Member]
Income Taxes [Abstract]
Statute of limitations related to income tax examinations	3 years
Foreign Jurisdictions [Member] | Maximum [Member]
Income Taxes [Abstract]
Statute of limitations related to income tax examinations	10 years

Derivatives and Hedging Activ_3

Derivatives and Hedging Activities, Fair Value of Derivative Instruments on the Balance Sheet (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) Derivatives	Dec. 31, 2023 USD ($) Derivatives
Derivatives and Hedging Activities [Abstract]
Loss to be reclassified to interest expense during next twelve months	$ (9,500)
Number of outstanding derivatives held | Derivatives	4	4
Notional amount	$ 200,000	$ 200,000
Interest Rate Swaps [Member] | Designated as Hedging Instrument [Member] | Prepaid Expenses and Other [Member]
Derivatives and Hedging Activities [Abstract]
Fair value, asset	9,451	8,955
Interest Rate Swaps [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives and Hedging Activities [Abstract]
Fair value, asset	$ 2,603	$ 3,734

Derivatives and Hedging Activ_4

Derivatives and Hedging Activities, Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss (Details) - Interest Rate Swaps [Member] - Designated as Hedging Instrument [Member] - Cash Flow Hedges [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Other Income (Expense), Net [Member]
Derivatives and Hedging Activities [Abstract]
Gain reclassified from accumulated other comprehensive loss into income	$ 2,643	$ 2,197
Other Comprehensive Loss [Member]
Derivatives and Hedging Activities [Abstract]
Gain (loss) recognized in OCI	$ 2,009	$ (810)

Segment Information, Revenue by

Segment Information, Revenue by Segment (Details) $ in Thousands		3 Months Ended
		Mar. 31, 2024 USD ($) Segment	Mar. 31, 2023 USD ($)
Segment Information [Abstract]
Number of reportable segments | Segment		9
Number of geographic segments | Segment		7
Number of Rhyz segments | Segment		2
Revenue by Segment [Abstract]
Revenue		$ 417,306	$ 481,462
Other [Member]
Revenue by Segment [Abstract]
Revenue		672	(115)
Operating Segment [Member] | Nu Skin [Member]
Revenue by Segment [Abstract]
Revenue		354,773	441,750
Operating Segment [Member] | Americas [Member]
Revenue by Segment [Abstract]
Revenue		75,031	101,157
Operating Segment [Member] | Mainland China [Member]
Revenue by Segment [Abstract]
Revenue		61,067	67,976
Operating Segment [Member] | Southeast Asia/Pacific [Member]
Revenue by Segment [Abstract]
Revenue		60,065	67,810
Operating Segment [Member] | Japan [Member]
Revenue by Segment [Abstract]
Revenue		44,236	52,606
Operating Segment [Member] | Europe & Africa [Member]
Revenue by Segment [Abstract]
Revenue		42,273	47,444
Operating Segment [Member] | South Korea [Member]
Revenue by Segment [Abstract]
Revenue		40,963	70,324
Operating Segment [Member] | Hong Kong/Taiwan [Member]
Revenue by Segment [Abstract]
Revenue		30,466	34,548
Operating Segment [Member] | Rhyz Investments [Member]
Revenue by Segment [Abstract]
Revenue		62,533	39,712
Operating Segment [Member] | Manufacturing [Member]
Revenue by Segment [Abstract]
Revenue	[1]	50,302	35,767
Operating Segment [Member] | Rhyz Other [Member]
Revenue by Segment [Abstract]
Revenue		12,231	3,945
Intersegment [Member] | Manufacturing [Member]
Revenue by Segment [Abstract]
Revenue		$ 8,600	$ 11,800
[1]The Rhyz Investments Manufacturing segment had $ 8.6 11.8

Segment Information, Segment Co

Segment Information, Segment Contribution (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Contribution [Abstract]
Operating income	$ 8,822	$ 16,064
Interest expense	7,325	4,888
Other income (expense), net	(396)	3,412
Income before provision for income taxes	1,101	14,588
Operating Segment [Member]
Segment Contribution [Abstract]
Operating income	69,170	86,955
Operating Segment [Member] | Nu Skin [Member]
Segment Contribution [Abstract]
Operating income	73,145	90,288
Operating Segment [Member] | Americas [Member]
Segment Contribution [Abstract]
Operating income	14,976	16,250
Operating Segment [Member] | Mainland China [Member]
Segment Contribution [Abstract]
Operating income	12,253	13,612
Operating Segment [Member] | Southeast Asia/Pacific [Member]
Segment Contribution [Abstract]
Operating income	11,084	12,471
Operating Segment [Member] | Japan [Member]
Segment Contribution [Abstract]
Operating income	12,006	12,908
Operating Segment [Member] | Europe & Africa [Member]
Segment Contribution [Abstract]
Operating income	3,276	3,638
Operating Segment [Member] | South Korea [Member]
Segment Contribution [Abstract]
Operating income	12,183	23,575
Operating Segment [Member] | Hong Kong/Taiwan [Member]
Segment Contribution [Abstract]
Operating income	7,367	7,834
Operating Segment [Member] | Rhyz Investments [Member]
Segment Contribution [Abstract]
Operating income	(3,975)	(3,333)
Operating Segment [Member] | Manufacturing [Member]
Segment Contribution [Abstract]
Operating income	1,967	(1,373)
Operating Segment [Member] | Rhyz Other [Member]
Segment Contribution [Abstract]
Operating income	(5,942)	(1,960)
Corporate and Other [Member]
Segment Contribution [Abstract]
Operating income	$ (60,348)	$ (70,891)

Segment Information, Depreciati

Segment Information, Depreciation and Amortization and Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Summarized Financial Information [Abstract]
Depreciation and amortization	$ 18,437	$ 16,983
Capital expenditures	12,281	11,487
Operating Segments [Member] | Nu Skin [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	4,306	5,363
Capital expenditures	3,104	4,737
Operating Segments [Member] | Americas [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	105	66
Capital expenditures	21	100
Operating Segments [Member] | Mainland China [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	2,774	2,775
Capital expenditures	2,689	4,035
Operating Segments [Member] | Southeast Asia/Pacific [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	249	280
Capital expenditures	9	64
Operating Segments [Member] | Japan [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	81	1,054
Capital expenditures	0	5
Operating Segments [Member] | Europe & Africa [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	273	282
Capital expenditures	165	119
Operating Segments [Member] | South Korea [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	245	453
Capital expenditures	22	154
Operating Segments [Member] | Hong Kong/Taiwan [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	579	453
Capital expenditures	198	260
Operating Segments [Member] | Rhyz Investments [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	5,221	4,016
Capital expenditures	1,984	1,481
Operating Segments [Member] | Manufacturing [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	3,335	3,424
Capital expenditures	1,349	1,481
Operating Segments [Member] | Rhyz Other [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	1,886	592
Capital expenditures	635	0
Corporate and Other [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	8,910	7,604
Capital expenditures	$ 7,193	$ 5,269

Acquisitions, LifeDNA (Details)

Acquisitions, LifeDNA (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 30, 2023	Mar. 31, 2024	Dec. 31, 2023
Fair Value of Assets Acquired [Abstract]
Goodwill		$ 230,768	$ 230,768
LifeDNA [Member]
Acquisitions [Abstract]
Percentage interest acquired	60%
Consideration paid, cash	$ 4,000
Consideration paid, conversion of previous SAFE	3,000
Consideration paid, convertible note	200
Gross purchase price	12,000
Fair Value of Assets Acquired [Abstract]
Intangible assets	7,300
Cash	1,700
Current assets	100
Accrued liabilities	900
Deferred tax liability	900
Goodwill	4,700
Measurement period adjustments to deferred tax liability and goodwill			$ 1,100
LifeDNA [Member] | Customer Relationships [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	600
Useful life		2 years
LifeDNA [Member] | Technology [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	1,700
Useful life		7 years
LifeDNA [Member] | Tradenames [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	1,000
Useful life		7 years
LifeDNA [Member] | Other Intangibles [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	$ 4,100
Useful life		7 years

Acquisitions, BeautyBio (Detail

Acquisitions, BeautyBio (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2024	Dec. 31, 2023
Fair Value of Assets Acquired [Abstract]
Goodwill		$ 230,768	$ 230,768
BeautyBio [Member]
Acquisitions [Abstract]
Percentage interest acquired	100%
Purchase price, net of cash acquired	$ 75,000
Cash acquired	1,500
Gross purchase price	76,500
Fair Value of Assets Acquired [Abstract]
Intangible assets	43,000
Cash	1,500
Accounts receivable	3,500
Inventory	10,300
Prepaid and other assets	800
Fixed assets	1,000
ROU operating lease asset	1,200
Lease liability	1,200
Accounts payable and accrued liabilities	2,500
Deferred tax liability	700
Goodwill	19,600
Measurement period adjustment to accounts receivable			(1,200)
Measurement period adjustment to inventory			(700)
Measurement period adjustment to accrued liabilities			(500)
Measurement period adjustment to deferred tax liability			700
Measurement period adjustment to intangible assets			(300)
Measurement period adjustment to goodwill			$ 2,400
BeautyBio [Member] | Customer Relationships [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	18,400
Useful life		9 years
BeautyBio [Member] | Technology [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	2,300
Useful life		19 years
BeautyBio [Member] | Tradenames [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	20,900
Useful life		19 years
BeautyBio [Member] | Other Intangibles [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	$ 1,400
Useful life		3 years

Acquisitions, Revenue and Pro F

Acquisitions, Revenue and Pro Forma Revenue (Details) - LifeDNA and BeautyBio [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Acquisitions [Abstract]
Unaudited pro forma revenue as if acquisitions occurred on January 1, 2023		$ 486.3
Rhyz Other [Member]
Acquisitions [Abstract]
Revenue since acquisitions	$ 5.3

Restructuring, 2022 Plan (Detai

Restructuring, 2022 Plan (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended		15 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Restructuring [Abstract]
Restructuring expense	$ 7,134	$ 9,787
2022 Plan [Member]
Restructuring [Abstract]
Cash restructuring charges					$ 40,800
Non-cash restructuring charges					12,500
Severance charges		4,000	$ 4,000	$ 20,100
Lease termination cost		1,900	1,900	7,400
Other associated restructuring costs		2,200	2,200	5,200
Impairment of fixed assets				8,200
Accelerated depreciation		1,700	1,700	900
Impairment of other intangible assets				1,700
Cash payments			19,800	21,000
Ending restructuring accrual			$ 0	11,700
Restructuring expense		9,787		43,494	53,281
2022 Plan [Member] | Operating Segment [Member] | Nu Skin [Member]
Restructuring [Abstract]
Restructuring expense		4,024		23,516	27,540
2022 Plan [Member] | Operating Segment [Member] | Americas [Member]
Restructuring [Abstract]
Restructuring expense		918		1,687	2,605
2022 Plan [Member] | Operating Segment [Member] | Mainland China [Member]
Restructuring [Abstract]
Restructuring expense		1,352		13,181	14,533
2022 Plan [Member] | Operating Segment [Member] | Southeast Asia/Pacific [Member]
Restructuring [Abstract]
Restructuring expense		131		1,809	1,940
2022 Plan [Member] | Operating Segment [Member] | Japan [Member]
Restructuring [Abstract]
Restructuring expense		1,515		699	2,214
2022 Plan [Member] | Operating Segment [Member] | Europe & Africa [Member]
Restructuring [Abstract]
Restructuring expense		(113)		2,143	2,030
2022 Plan [Member] | Operating Segment [Member] | South Korea [Member]
Restructuring [Abstract]
Restructuring expense		422		1,533	1,955
2022 Plan [Member] | Operating Segment [Member] | Hong Kong/Taiwan [Member]
Restructuring [Abstract]
Restructuring expense		(201)		2,464	2,263
2022 Plan [Member] | Operating Segment [Member] | Rhyz Investments [Member]
Restructuring [Abstract]
Restructuring expense		13		401	414
2022 Plan [Member] | Operating Segment [Member] | Manufacturing [Member]
Restructuring [Abstract]
Restructuring expense		13		401	414
2022 Plan [Member] | Operating Segment [Member] | Rhyz Other [Member]
Restructuring [Abstract]
Restructuring expense		0		0	0
2022 Plan [Member] | Corporate and Other [Member]
Restructuring [Abstract]
Restructuring expense		$ 5,750		$ 19,577	$ 25,327

Restructuring, 2023 Plan (Detai

Restructuring, 2023 Plan (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Mar. 31, 2024
Restructuring [Abstract]
Restructuring expense	$ 7,134		$ 9,787
2023 Plan [Member]
Restructuring [Abstract]
Severance charges	4,100	$ 10,000
Other associated restructuring costs	2,000
Accelerated depreciation	1,000
Cash payments	7,000	300
Ending restructuring accrual	8,800	9,700		$ 8,800
Restructuring expense	7,134	10,003		17,137
2023 Plan [Member] | Operating Segment [Member] | Nu Skin [Member]
Restructuring [Abstract]
Restructuring expense	5,661	5,356		11,017
2023 Plan [Member] | Operating Segment [Member] | Americas [Member]
Restructuring [Abstract]
Restructuring expense	3,145	598		3,743
2023 Plan [Member] | Operating Segment [Member] | Mainland China [Member]
Restructuring [Abstract]
Restructuring expense	1,017	2,910		3,927
2023 Plan [Member] | Operating Segment [Member] | Southeast Asia/Pacific [Member]
Restructuring [Abstract]
Restructuring expense	307	862		1,169
2023 Plan [Member] | Operating Segment [Member] | Japan [Member]
Restructuring [Abstract]
Restructuring expense	24	0		24
2023 Plan [Member] | Operating Segment [Member] | Europe & Africa [Member]
Restructuring [Abstract]
Restructuring expense	677	554		1,231
2023 Plan [Member] | Operating Segment [Member] | South Korea [Member]
Restructuring [Abstract]
Restructuring expense	134	0		134
2023 Plan [Member] | Operating Segment [Member] | Hong Kong/Taiwan [Member]
Restructuring [Abstract]
Restructuring expense	357	432		789
2023 Plan [Member] | Operating Segment [Member] | Rhyz Investments [Member]
Restructuring [Abstract]
Restructuring expense	0	0		0
2023 Plan [Member] | Operating Segment [Member] | Manufacturing [Member]
Restructuring [Abstract]
Restructuring expense	0	0		0
2023 Plan [Member] | Operating Segment [Member] | Rhyz Other [Member]
Restructuring [Abstract]
Restructuring expense	0	0		0
2023 Plan [Member] | Corporate and Other [Member]
Restructuring [Abstract]
Restructuring expense	$ 1,473	4,647		$ 6,120
2023 Plan [Member] | Minimum [Member]
Restructuring [Abstract]
Estimated total charges under restructuring program		20,000
2023 Plan [Member] | Maximum [Member]
Restructuring [Abstract]
Estimated total charges under restructuring program		$ 25,000